EMBC 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

EMBC ▲ +7.99% at T+20d

LONG call ✓ call won +7.99% · α vs SPY -1.33% · entry $8.89 → $9.60

Next anchor: T+60d in 6d

Currently $3.31 · -62.77% from $8.89 entry

Entry anchored
Mar 19, 03:59 PM ET
via Databento tick

T+1d

+1.57%

call +1.57% · α +0.47%

$9.03

settled 3mo ago

T+5d

-3.60%

call -3.60% · α -1.45%

$8.57

settled 3mo ago

T+20d

+7.99%

call +7.99% · α -1.33%

$9.60

settled 7w ago

T+60d

—

call — · α —

—

in 6d

Price Chart

Loading chart...

Executive Summary

Embecta Corp. (EMBC) has agreed to acquire Owen Mumford Holdings Limited, a UK-based medical device manufacturer, in a deal valued at up to £150 million. The transaction includes an upfront payment of £100 million and up to £50 million in earn-out payments tied to sales of the Aidaptus auto-injector platform. The acquisition is expected to expand Embecta's product portfolio and commercial reach in chronic care markets.

Key Financial Metrics

Deal Value

$150.0M

Actionable Insight

Monitor Owen Mumford's Aidaptus product sales performance over the next three years, as this will determine whether Embecta pays the full £50 million earn-out. The acquisition positions Embecta to expand in the drug-delivery device market, particularly in obesity, diabetes, and autoimmune disease treatments.

Key Facts

Embecta is acquiring Owen Mumford Holdings Limited for up to £150 million
The deal includes an upfront payment of £100 million and up to £50 million in earn-out payments
Earn-out payments are tied to net sales of the Aidaptus auto-injector platform over three years
Owen Mumford generated £69.4 million in net revenue during fiscal year 2025
The acquisition is expected to close in Embecta's fiscal third quarter of 2026
Embecta expects the acquisition to contribute to revenue growth in fiscal year 2027 and beyond

Financial Impact

Up to £150 million total deal value, with £100 million upfront and £50 million in potential earn-outs

revenuedebt

Risk Factors

Integration challenges between the two companies
Failure to achieve the sales targets needed to realize the full earn-out value

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0000947871-26-000310
Document: ss6090062_8k.htm	0000947871-26-000310
Document: ss6090062_ex9901.htm	0000947871-26-000310
Document: 0000947871-26-000310-index-headers.html	0000947871-26-000310
Document: 0000947871-26-000310-index.html	0000947871-26-000310
Document: 0000947871-26-000310.txt	0000947871-26-000310

5 reports for EMBC

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +13.85%May 5, 2026

Filters

Reports for EMBC — sortable, filterable
	Type				Now
May 15, 2026 25d ago	8-K MIXED ★ 6/10	$3.14 $3.32	▲ +5.73%	▲ +4.77%	$3.31 (+5.41%)
May 5, 2026 5w ago	8-K BEARISH ★ 8/10	$3.90 $3.36	▲ +13.85%	▲ +15.83%	$3.31 (+15.13%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$9.21 $8.89	▼ −3.47%	▼ −3.53%	$3.31 (−64.06%)
Mar 20, 2026 11w ago	8-K BULLISH ★ 7/10	$8.89 $8.57	▼ −3.60%	▼ −1.45%	$3.31 (−62.77%)
Mar 19, 2026 11w ago	Press Release BULLISH ★ 7/10	$9.12 $8.87	▼ −2.74%	▼ −0.53%	$3.31 (−63.71%)

US Market Status

Market Closed — Opens Thu (11h 21m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access